circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
===== Romania ===== Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
== External links == Media related to Ajinomoto at Wikimedia Commons Official website "Company history books (Shashi)". Shashi Interest Group. April 2016. Wiki collection of bibliographic works on Ajinomoto
=== Redox === Silver(I) salts are mild oxidants, as implicated by their role in silver-based photography and the staining of skin by silver metal upon contact with silver nitrate solutions. Characteristically, silver nitrate reacts with pieces of copper to form hairlike crystals of silver metal and a blue solution of copper nitrate:
== Professional activities == Dr. Goldstein was the co-founder and first president and scientific director of the Institute for Advanced Studies in Aging and Geriatric Medicine, a nonprofit research institute that supports research and educational activities. He also served as a member of the board of trustees of the Albert Sabin Vaccine Institute and of the board of directors of the Richard B. and Lynn V. Cheney Cardiovascular Institute. Currently, he serves as the chairman of the board and chief scientific advisor for RegeneRx Biopharmaceuticals, a public company developing novel wound-healing and remodeling therapeutics.
There appears to be no consensus on the existence of substances that may have at one time been named as vitamins Q, R, T, V, W, X, Y or Z. "Vitamin N" is a term popularized for the mental health benefits of spending time in nature settings. "Vitamin I" is slang among athletes for frequent/daily consumption of ibuprofen as a pain-relieving treatment.
Sources: en.wikipedia.org
Also, he claimed a brief dispute with The Rock was resolved quickly upon his return, and that none of his disputes with the talent roster continued or played the major part in his departure. In February, Austin returned at No Way Out on February 23 by defeating Eric Bischoff. Austin would wrestle only one match between then and WrestleMania, in another short match against Bischoff on Raw. He entered a feud with The Rock, who returned around the same time as a smug, Hollywood sell-out heel. The Rock was offended that the WWE fans voted for Austin in a WWE Magazine poll to determine the 'Superstar of the Decade'. He expressed his frustration at having never defeated Austin at WrestleMania, and challenged Austin to a match at WrestleMania XIX on March 30. Austin was then defeated by The Rock at WrestleMania XIX, in what would be Austin's final match for 19 years.
Class 350: 350 °F (176.7 °C) at 100% relative humidity for paper records, which keeps the contents below the charring point of 420 °F (215.6 °C); Class 150: 150 °F (65.6 °C) at 85% relative humidity for photographic, magnetic, or similar non-paper records; Class 125: 125 °F (51.7 °C) at 80% relative humidity for the more heat-sensitive floppy disks. A safe rated UL Class 150 or UL Class 125 and intended to hold only computer media is sometimes called a media safe, and Class 125 units are also known as data safes. NFPA 232 requires that the vault door be a listed vault door with a fire-resistive rating that meets or exceeds that of the vault walls. Wall penetrations must be sealed to prevent the intrusion of smoke, heat, flame, or water, with a listed fire-rated through-penetration assembly for general penetrations and listed fire-rated material for penetrations for sprinkler piping, electric lighting, conduit, and power-limited circuits, in each case with a rating that meets or exceeds that of the vault. Ventilation openings must be as small as possible, protected to maintain the required rating of the wall, and fitted with smoke dampers activated by automatic sensing devices. Paper water-damaged in a fire can be remediated by vacuum freeze-drying, in which water is sublimed from the liquid state to a vapor, causing less ink bleeding and planar distortion than air or desiccant drying.
Some psychiatrists regarded seizures as therapeutic and patients were sometimes also given electroconvulsive therapy or cardiazol/metrazol convulsive therapy during the coma, or on the day of the week when they didn't have insulin treatment. When they were not in a coma, insulin coma patients were kept together in a group and given special treatment and attention. One handbook for psychiatric nurses, written by British psychiatrist Eric Cunningham Dax, instructs nurses to take their insulin patients out walking and occupy them with games and competitions, flower-picking and map-reading, etc. Patients required continuous supervision as there was a danger of hypoglycemic aftershocks after the coma. In "modified insulin therapy", used in the treatment of neurosis, patients were given lower (sub-coma) doses of insulin.
By applying Menon's idea of creating a meal based on a single food, as this culinary writer had indicated in 1755, in Les Soupers de la cour ou l'art de travailler toutes sortes d'aliments pour servir les meilleures tables, suivant les quatre saisons with his Menu d'un repas servi tout en mouton, Menu d'un repas servi tout en cochon and Menu d'un repas servi tout en œufs, Parmentier demonstrates to a group of influential people in good society, including Nicolas François de Neufchâteau, that the potato can be used, in different forms, at different times of the meal. He thus succeeded in promoting the vegetable on the culinary level, which still leaves its mark on people's minds for a long time to come: "The guests, who were all distinguished men, people in credit or people of spirit, went to the fashionable salons to tell the news of their dinner where the potato reigned without rival", wrote the Semaine des familles, nearly a century later. Parmentier took every opportunity to promote the tuber: when he received Arthur Young on October 24, 1787, the menu was based on potatoes and, for the first time, his sister Marie-Suzanne Houzeau served, among other dishes, steamed potatoes. However, the use of this tuber did not become widespread in France until the end of the 19th century, when Alexandre Dumas felt the need to affirm its healthiness:
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.